相似文献
1
Eli Lilly enters venture capital arena.
Nat Biotechnol. 2001 Nov;19(11):997-8. doi: 10.1038/nbt1101-997.
2
The stampede to convertibles.
Nat Biotechnol. 2003 Aug;21(8):855. doi: 10.1038/nbt0803-855.
3
Sustaining agbiotechnology through lean times.
Nat Biotechnol. 2003 Sep;21(9):996-1002. doi: 10.1038/nbt0903-996.
4
Early-stage returns?
Nat Biotechnol. 2006 Nov;24(11):1335-40. doi: 10.1038/nbt1106-1335.
5
Evolving symbiosis--venture capital and biotechnology.
Nat Biotechnol. 2003 Sep;21(9):983-4. doi: 10.1038/nbt0903-983.
6
Trends in biopharmaceutical IPOS: 1996-2005.
J Health Care Finance. 2006 Winter;33(2):39-54.
7
Biotechnology partnerships--medicine for an ailing industry?
Nat Biotechnol. 2003 Aug;21(8):847-8. doi: 10.1038/nbt0803-847.
8
The rise of European venture capital for biotechnology.
Nat Biotechnol. 2003 Nov;21(11):1287-91. doi: 10.1038/nbt1103-1287.
9
Biotech venture capital--it's not too late to be early.
Nat Biotechnol. 2005 Apr;23(4):417-8. doi: 10.1038/nbt0405-417.
10
The 802 million dollars fallacy.
Nat Biotechnol. 2004 Sep;22(9):1076. doi: 10.1038/nbt0904-1076a.
Zotero 插件